Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Vaxcyte stock

PCVX
US92243G1085
A2P6R6

Price

92.68
Today +/-
-4.91
Today %
-5.43 %
P

Vaxcyte stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Vaxcyte stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Vaxcyte stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Vaxcyte stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Vaxcyte's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Vaxcyte Stock Price History

DateVaxcyte Price
11/14/202492.68 undefined
11/13/202497.85 undefined
11/12/202499.38 undefined
11/11/2024103.64 undefined
11/8/2024106.67 undefined
11/7/2024102.70 undefined
11/6/2024104.07 undefined
11/5/2024107.56 undefined
11/4/2024106.49 undefined
11/1/2024107.29 undefined
10/31/2024106.35 undefined
10/30/2024106.11 undefined
10/29/2024105.56 undefined
10/28/2024112.80 undefined
10/25/2024112.94 undefined
10/24/2024112.32 undefined
10/23/2024112.14 undefined
10/22/2024112.66 undefined
10/21/2024115.45 undefined
10/18/2024115.50 undefined
10/17/2024115.61 undefined

Vaxcyte Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Vaxcyte, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Vaxcyte from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Vaxcyte’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Vaxcyte. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Vaxcyte’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Vaxcyte’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Vaxcyte’s growth potential.

Vaxcyte Revenue, EBIT and net profit per share

DateVaxcyte RevenueVaxcyte EBITVaxcyte Net Income
2029e1.27 B undefined0 undefined150.65 M undefined
2028e336.84 M undefined-340.01 M undefined-308.93 M undefined
2027e69.67 M undefined-640.34 M undefined-458.95 M undefined
2026e0 undefined-621.11 M undefined-658.12 M undefined
2025e0 undefined-627.52 M undefined-598.59 M undefined
2024e0 undefined-565.82 M undefined-517.99 M undefined
20230 undefined-393.04 M undefined-402.27 M undefined
20220 undefined-209.26 M undefined-223.49 M undefined
20210 undefined-103.67 M undefined-100.08 M undefined
20200 undefined-89.58 M undefined-89.22 M undefined
20190 undefined-54.15 M undefined-50.27 M undefined
20180 undefined-35.53 M undefined-29.49 M undefined
20170 undefined-17.83 M undefined-17.24 M undefined

Vaxcyte Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20172018201920202021202220232024e2025e2026e2027e2028e2029e
00000000000.070.341.27
-----------386.96278.57
-------------
0000000000000
-17-29-50-89-100-223-402-517-598-658-458-308150
-70.5972.4178.0012.36123.0080.2728.6115.6710.03-30.40-32.75-148.70
48.3948.3948.3929.5551.9264.8897.16000000
-------------
Details

Keystats

ⓘ

Revenue and Growth

The Vaxcyte Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Vaxcyte is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (B)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (B)
2017201820192020202120222023
             
0.040.070.060.390.250.931.08
0000000
0000000
0000000
0.20.62.72.810.411.215.73
0.040.070.060.390.260.941.1
33.43.43.335.931.6110.62
000027.126.5162.68
0000000
0000000
0000000
0.30.70.60.655.438.67
3.34.143.96863.5311.96
0.040.070.070.390.321.011.41
             
60.1117.8160.30.10.10.10.1
0000.540.581.482.16
-29.6-59.1-109.3-198.6-298.6-522.1-924.39
0000-200-400179
0000000
0.030.060.050.350.280.951.24
1.82.83.429.86.89.814.59
2.53.97.717.12230.7130.75
0000000
0000000
0000000
4.36.711.146.928.840.5145.34
3.83.60.50000
0000000
0.70.40.30.111.61222.11
4.540.80.111.61222.11
8.810.711.94740.452.5167.45
0.040.070.070.390.321.011.41
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Vaxcyte provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Vaxcyte's financial health and stability.

Assets

Vaxcyte's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Vaxcyte must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Vaxcyte after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Vaxcyte's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2017201820192020202120222023
-17-29-50-89-100-223-402
0111123
0000000
11335-371281
0-3011246169
0000000
0000000
-14-30-47-46-121-170-296
-1-1-1-1-6-5-67
-1-1-1-1-21274-773
0000-20580-705
0000000
0000000
44624237817862643
43624137417861639
---1.00-3.00---3.00
0000000
2729-7327-316765-436
-16.18-32.24-48.35-47.79-127.95-176.45-364.67
0000000

Vaxcyte stock margins

The Vaxcyte margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Vaxcyte. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Vaxcyte.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Vaxcyte's sales revenue. A higher gross margin percentage indicates that the Vaxcyte retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Vaxcyte's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Vaxcyte's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Vaxcyte's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Vaxcyte. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Vaxcyte's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Vaxcyte Margin History

Vaxcyte Gross marginVaxcyte Profit marginVaxcyte EBIT marginVaxcyte Profit margin
2029e0 %0 %11.84 %
2028e0 %-100.94 %-91.71 %
2027e0 %-919.16 %-658.79 %
2026e0 %0 %0 %
2025e0 %0 %0 %
2024e0 %0 %0 %
20230 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %

Vaxcyte Stock Sales Revenue, EBIT, Earnings per Share

The Vaxcyte earnings per share therefore indicates how much revenue Vaxcyte has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Vaxcyte earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Vaxcyte's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Vaxcyte’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Vaxcyte's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Vaxcyte Revenue, EBIT and net profit per share

DateVaxcyte Sales per ShareVaxcyte EBIT per shareVaxcyte Earnings per Share
2029e10.21 undefined0 undefined1.21 undefined
2028e2.7 undefined0 undefined-2.48 undefined
2027e0.56 undefined0 undefined-3.68 undefined
2026e0 undefined0 undefined-5.28 undefined
2025e0 undefined0 undefined-4.8 undefined
2024e0 undefined0 undefined-4.16 undefined
20230 undefined-4.05 undefined-4.14 undefined
20220 undefined-3.23 undefined-3.44 undefined
20210 undefined-2 undefined-1.93 undefined
20200 undefined-3.03 undefined-3.02 undefined
20190 undefined-1.12 undefined-1.04 undefined
20180 undefined-0.73 undefined-0.61 undefined
20170 undefined-0.37 undefined-0.36 undefined

Vaxcyte business model

Vaxcyte Inc is a global biopharmaceutical company focused on the discovery, development, and commercialization of vaccines for various diseases. The company was founded in 2018 and is headquartered in Foster City, California. Vaxcyte is one of the most popular companies on Eulerpool.com.

Vaxcyte SWOT Analysis

Strengths

Vaxcyte Inc has several strengths that contribute to its competitive advantage:

  • Strong Research and Development capabilities enable the company to innovate and develop novel vaccines.
  • Partnerships with leading academic institutions and global pharmaceutical companies enhance knowledge sharing and expand market reach.
  • Robust pipeline of vaccine candidates targeting various infectious diseases positions the company for future growth.
  • Established manufacturing capabilities ensure efficient production and supply of vaccines.

Weaknesses

Despite its strengths, Vaxcyte Inc faces certain weaknesses that may impact its performance:

  • Limited market presence compared to established vaccine manufacturers may create challenges in market penetration.
  • Dependency on successful clinical trials for pipeline vaccines introduces uncertainties in the development process.
  • Relatively smaller scale of operations may hinder the company's ability to compete with larger players in terms of resources and global reach.

Opportunities

Vaxcyte Inc can leverage the following opportunities to fuel its growth:

  • Increasing global demand for vaccines driven by rising awareness of preventive healthcare.
  • Expanding market for vaccines in emerging economies presents untapped growth potential.
  • Collaborations and strategic partnerships with existing players can help broaden the company's product portfolio and market access.
  • Advancements in technology enable the development of more effective and efficient vaccine production processes.

Threats

Vaxcyte Inc should be mindful of the following threats that could impact its business:

  • Intense competition within the vaccine industry, with established players dominating market share.
  • Stringent regulatory requirements and approval processes for vaccine development and commercialization.
  • Potential risks associated with adverse events or side effects of vaccines, leading to reputational damage and legal liabilities.
  • Pandemics and outbreaks may result in increased demand for vaccines, but also lead to supply chain disruptions and operational challenges.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Vaxcyte Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Vaxcyte historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Vaxcyte shares outstanding

The number of shares was Vaxcyte in 2023 — This indicates how many shares 97.158 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Vaxcyte earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Vaxcyte's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Vaxcyte’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Vaxcyte's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Vaxcyte.

Vaxcyte latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2024-1.16 -0.83  (28.3 %)2024 Q3
6/30/2024-1 -1.1  (-9.49 %)2024 Q2
3/31/2024-1.19 -0.85  (28.7 %)2024 Q1
12/31/2023-1.09 -1.82  (-66.45 %)2023 Q4
9/30/2023-0.85 -0.91  (-6.52 %)2023 Q3
6/30/2023-0.76 -0.7  (7.88 %)2023 Q2
3/31/2023-0.84 -0.7  (16.88 %)2023 Q1
12/31/2022-0.95 -1.02  (-7.53 %)2022 Q4
9/30/2022-0.85 -0.93  (-8.98 %)2022 Q3
6/30/2022-0.7 -0.8  (-13.67 %)2022 Q2
1
2

Eulerpool ESG Scorecard© for the Vaxcyte stock

Eulerpool World ESG Rating (EESG©)

45/ 100

🌱 Environment

49

👫 Social

45

🏛️ Governance

41

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Vaxcyte shareholders

%
Name
Stocks
Change
Date
11.54700 % Fidelity Management & Research Company LLC14,392,175-238,4666/30/2024
7.84422 % The Vanguard Group, Inc.9,777,04058,6306/30/2024
7.11562 % Janus Henderson Investors8,868,9071,195,0396/30/2024
6.58196 % RA Capital Management, LP8,203,75406/30/2024
6.32651 % BlackRock Institutional Trust Company, N.A.7,885,361314,3856/30/2024
3.68507 % Wellington Management Company, LLP4,593,066-326,3046/30/2024
3.31639 % Capital Research Global Investors4,133,544-6,9776/30/2024
3.22737 % T. Rowe Price Investment Management, Inc.4,022,589469,6226/30/2024
2.70150 % State Street Global Advisors (US)3,367,14730,0556/30/2024
2.47001 % T. Rowe Price Associates, Inc.3,078,615-8,2126/30/2024
1
2
3
4
5
...
10

Vaxcyte Executives and Management Board

Mr. Grant Pickering(55)
Vaxcyte Chief Executive Officer, Co-Founder, Director (since 2013)
Compensation 13.66 M
Mr. James Wassil(53)
Vaxcyte Chief Operating Officer, Executive Vice President
Compensation 6.99 M
Mr. Andrew Guggenhime(53)
Vaxcyte President, Chief Financial Officer
Compensation 6.9 M
Mr. Mikhail Eydelman(42)
Vaxcyte Senior Vice President, Chief Compliance Officer, General Counsel, Company Secretary
Compensation 5.01 M
Mr. Paul Sauer(61)
Vaxcyte Senior Vice President - Process Development and Manufacturing
Compensation 2.35 M
1
2
3
4

Vaxcyte Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Lonza Group Stock
Lonza Group
SupplierCustomer0,230,530,27-0,020,24-0,35
Sutro Biopharma Stock
Sutro Biopharma
SupplierCustomer-0,340,140,23-0,280,19-0,28
1

Most common questions regarding Vaxcyte

What values and corporate philosophy does Vaxcyte represent?

Vaxcyte Inc embodies a strong commitment to advancing global health through innovative vaccine solutions and effective disease prevention. With a core philosophy rooted in scientific excellence, Vaxcyte strives to develop and deliver transformative immunizations to protect vulnerable populations. The company's values revolve around integrity, collaboration, and persistence in the pursuit of groundbreaking vaccine research and development. Vaxcyte's dedicated team of experts works tirelessly to address unmet medical needs, focusing on infectious diseases and finding efficient ways to enhance public health. Through its unwavering dedication and pioneering spirit, Vaxcyte Inc aims to make a lasting impact in the field of immunization.

In which countries and regions is Vaxcyte primarily present?

Vaxcyte Inc is primarily present in the United States.

What significant milestones has the company Vaxcyte achieved?

Vaxcyte Inc, a leading biotechnology company, has achieved numerous significant milestones. Notably, the company successfully completed its initial public offering (IPO) in June 2020, raising substantial funds to drive its innovative research and development efforts. Vaxcyte has also made remarkable progress in the development of its investigational pneumococcal conjugate vaccine, VAX-24. This vaccine candidate has shown promising results in clinical trials, demonstrating its potential to prevent pneumococcal diseases in both pediatric and adult populations. Furthermore, Vaxcyte has established strategic partnerships and collaborations with renowned organizations and experts in the field, further fueling its growth and market presence. Overall, Vaxcyte Inc has achieved significant milestones in its pursuit of improving global public health through innovative vaccine solutions.

What is the history and background of the company Vaxcyte?

Vaxcyte Inc is a leading biotechnology company specializing in the development of novel vaccines to combat infectious diseases. Established in [year], Vaxcyte has a rich history of pioneering research and collaboration with renowned institutions. With a mission to enhance global health through innovative vaccine solutions, the company has made significant strides in targeting various pathogens. Headquartered in [location], Vaxcyte has amassed a team of talented scientists and industry experts dedicated to improving public health worldwide. Leveraging cutting-edge technologies and a robust pipeline, Vaxcyte Inc continues to make remarkable advancements in the field of vaccine development.

Who are the main competitors of Vaxcyte in the market?

The main competitors of Vaxcyte Inc in the market include companies such as Pfizer, Moderna, Novavax, and AstraZeneca.

In which industries is Vaxcyte primarily active?

Vaxcyte Inc is primarily active in the healthcare sector.

What is the business model of Vaxcyte?

Vaxcyte Inc. is a biotechnology company specializing in the development and commercialization of innovative vaccines to prevent infectious diseases. Their business model revolves around the research, development, and production of novel vaccines that target unmet medical needs. Vaxcyte Inc. employs advanced technologies and scientific expertise to create effective vaccines against prevalent and emerging infectious diseases, focusing on areas such as pneumonia and other bacterial infections. By addressing global health challenges through their vaccine portfolio, Vaxcyte Inc. aims to improve public health and contribute to the prevention and control of various infectious diseases worldwide.

What is the P/E ratio of Vaxcyte 2024?

The Vaxcyte P/E ratio is -17.38.

What is the P/S ratio of Vaxcyte 2024?

The Vaxcyte P/S ratio is 0.

What is the Quality Investing of Vaxcyte?

The Quality Investing for Vaxcyte is 2/10.

What is the revenue of Vaxcyte 2024?

The revenue cannot currently be calculated for Vaxcyte.

How high is the profit of Vaxcyte 2024?

The expected Vaxcyte profit is -517.99 M USD.

What is the business model of Vaxcyte

Vaxcyte Inc is a biopharmaceutical company specializing in the development and commercialization of vaccines. The company was founded in 2018 in California and has since developed a variety of innovative technologies and platforms to combat a wide range of infectious diseases. Vaxcyte's business model is based on the development and commercialization of vaccines for diseases that currently have a high medical need. The company uses a recognized technology platform to identify potential vaccine candidates and conducts comprehensive clinical trials to ensure the effectiveness and safety of vaccines. Vaxcyte has particularly specialized in vaccines against pneumococcal infections, which can lead to serious illnesses such as pneumonia, meningitis, and sepsis. The company also has a wide range of vaccines in the pipeline targeting other severe infectious diseases, including chlamydia, gonorrhea, and RSV (respiratory syncytial virus). Vaxcyte has also developed a specialized technology platform to expand the potential of therapies aiming to remove antibiotics from the vaccine manufacturing process. Vaxcyte also maintains relationships with partners and investors who support its funding and business development. The company also receives external support as it has strong connections to academic institutions and national and international regulatory authorities such as the FDA and EMA, which grant important approvals for clinical trials and marketing authorizations. Vaxcyte aims to ensure successful development and commercialization of vaccines that are effective and safe through adequate regulation and industry knowledge. The company strives to optimize the end-to-end development of vaccines by using its technology to identify vaccine candidates with high potential for success in combating serious infectious diseases. In addition to the above-mentioned business areas, Vaxcyte also offers product services, particularly in collaboration with other companies looking to introduce products or technologies to the marketplace. By providing expertise in pharmacology, development, and procedural processes, Vaxcyte can help companies turn their innovative ideas into functional products. Overall, Vaxcyte's business model aims to develop innovative and effective vaccine solutions for a variety of serious infectious diseases to address global health needs. The use of cutting-edge technology and collaboration with other companies forms the foundation for the company's success.

What is the Vaxcyte dividend?

Vaxcyte pays a dividend of 0 USD distributed over payouts per year.

How often does Vaxcyte pay dividends?

The dividend cannot currently be calculated for Vaxcyte or the company does not pay out a dividend.

What is the Vaxcyte ISIN?

The ISIN of Vaxcyte is US92243G1085.

What is the Vaxcyte WKN?

The WKN of Vaxcyte is A2P6R6.

What is the Vaxcyte ticker?

The ticker of Vaxcyte is PCVX.

How much dividend does Vaxcyte pay?

Over the past 12 months, Vaxcyte paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Vaxcyte is expected to pay a dividend of 0 USD.

What is the dividend yield of Vaxcyte?

The current dividend yield of Vaxcyte is .

When does Vaxcyte pay dividends?

Vaxcyte pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Vaxcyte?

Vaxcyte paid dividends every year for the past 0 years.

What is the dividend of Vaxcyte?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Vaxcyte located?

Vaxcyte is assigned to the 'Health' sector.

Wann musste ich die Aktien von Vaxcyte kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Vaxcyte from 11/16/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/16/2024.

When did Vaxcyte pay the last dividend?

The last dividend was paid out on 11/16/2024.

What was the dividend of Vaxcyte in the year 2023?

In the year 2023, Vaxcyte distributed 0 USD as dividends.

In which currency does Vaxcyte pay out the dividend?

The dividends of Vaxcyte are distributed in USD.

All fundamentals about Vaxcyte

Our stock analysis for Vaxcyte Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Vaxcyte Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.